about
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.Fractionated Stereotactic Radiotherapy for Facial Nerve Schwannomas.A randomized trial of bevacizumab for newly diagnosed glioblastomaWhole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.Genetic landscape of extreme responders with anaplastic oligodendroglioma.Radiosurgery for the treatment of dominant hemisphere periventricular heterotopia and intractable epilepsy in a series of three patients.EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324.Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomasPrimary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-diMultifocal glioblastoma multiforme: prognostic factors and patterns of progression.Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma.Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214.Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis.Active Breathing Coordinator reduces radiation dose to the heart and preserves local control in patients with left breast cancer: report of a prospective trialPhase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.Prognostic factors in non-small cell lung cancer.Normal-tissue toxicities of thoracic radiation therapy: esophagus, lung, and spinal cord as organs at risk.Fractionated stereotactic radiotherapy for the treatment of large arteriovenous malformations with or without previous partial embolization.Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214.Integration of surgery with fractionated stereotactic radiotherapy for treatment of nonfunctioning pituitary macroadenomas.Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotheTreatment-related esophagitis.Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration.Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA).Fractionated stereotactic radiation therapy improves cranial neuropathies in patients with skull base meningiomas: a retrospective cohort study.Stage III lung cancer: two or three modalities? The continued role of thoracic radiotherapy.Radiation dose-volume effects in the esophagusA phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomasThe addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320Cicatricial alopecia secondary to radiation therapy: case report and review of the literature.Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235.Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignanciesNet clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.Biologically conformal treatment: biomarkers and functional imaging in radiation oncology.Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of nonacoustic cranial nerve schwannomas.
P50
Q30275188-5D8FE933-67D9-41A3-B1B6-5655E537EC4CQ30364557-9BE9AC71-EED3-48C0-99D6-C78F629F008FQ30410163-2507DC07-535B-4F6B-B024-C901DA0E8346Q31065424-A713E1C1-7E50-43E0-A344-2EA65E1F006EQ33829209-9EE5DCFA-68BB-436C-9C82-1A6144AB7661Q34115019-F9B69479-0C6F-4340-B627-33A22FC930A8Q34216725-58C32F75-9738-4BC0-848F-F25413E2B746Q34315691-2BD0BAB1-5EDD-44F5-BD15-67851EEF3C01Q34507660-DED1341B-A08D-40C6-86AD-6D9EC6DCF14BQ34627972-12AF5E4B-BA4B-419B-A642-22595D15E14AQ34633068-66B34151-078A-4DA9-B5DF-35B6F75FD68DQ34666837-6B739197-DD18-427E-BB34-564FF2732361Q34666843-3378C210-C2C0-4065-BB12-9443019602CDQ34900706-CEE4CDA8-305F-49CE-A130-E9A32F8D32D5Q35023433-53061702-7348-4ABC-98EE-2A3609C3693DQ35085561-2F17C815-ED6C-47EE-9164-E23E27FA1184Q35207344-F8D6391A-33C0-482F-97A9-115C44D2A55BQ35474006-AC1C9BA4-FFDC-4960-B2F4-E892CC655F6DQ35543207-981C48BA-0DDC-4DF8-8403-B3B14E50C7ECQ35684106-D10E4617-3FE5-4CBE-A1FB-41E6D87819A8Q35873883-1EB3DD4F-D7B9-45B8-AD68-3C1B2AB7198FQ35972302-02A0860C-EB9E-4881-95F1-4781E2A61F2CQ35983692-CDA02685-1C91-4E84-A1D1-5DDAF72C1FD0Q36039661-AE8B4104-C341-47D6-8471-7D749D84934BQ36052330-91410F6A-C7AE-44E1-A2A8-3B166FEE23FAQ36193575-47742D02-4F39-454C-9E72-44A5F62E1162Q36193596-EFE8F0B2-4188-4BA7-B510-23AA0D11E662Q36428221-AB425849-A2CC-4ED7-8CB3-231ACA79F7BCQ36552448-207610A3-CD05-4F4D-AF1E-B06CA8975078Q36616216-639AC527-EA49-41CD-AAC4-1E4E7487FDAAQ36655289-E18B8901-E10B-4B7E-B692-25DB21A5489DQ36792681-83B5F36B-881A-4784-98BD-E853ADF853CEQ36823982-DD2D1BFD-87C1-445E-BF93-EB7138D24855Q37087347-95203AA7-4737-42BA-9DB4-46E2DF277ADAQ37149281-B10538F9-D8CB-403C-8316-7AA7E03ECE5BQ37180546-95017A43-69FE-49FB-BA6C-314C9B0CF0B3Q37230020-E1DEDF0C-D757-45B9-B380-0C485394AC7FQ37278376-1F979072-5225-4E78-9A81-38374E5E2A14Q37298667-A8B79C98-F802-4E1E-A41E-8058F64B2125Q37316468-B837CBC2-3A2C-410F-B734-8170A043CBB3
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maria Werner-Wasik
@ast
Maria Werner-Wasik
@en
Maria Werner-Wasik
@es
Maria Werner-Wasik
@nl
type
label
Maria Werner-Wasik
@ast
Maria Werner-Wasik
@en
Maria Werner-Wasik
@es
Maria Werner-Wasik
@nl
prefLabel
Maria Werner-Wasik
@ast
Maria Werner-Wasik
@en
Maria Werner-Wasik
@es
Maria Werner-Wasik
@nl
P106
P21
P31
P496
0000-0002-9222-2668